Related Experiment Video
Updated: Jun 19, 2026
06:18
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Low circulating androgens and mortality risk in heart failure
G Güder1, S Frantz, J Bauersachs
1Medizinische Klinik und Poliklinik I - Herz-Kreislaufzentrum, Klinikum der Universität Würzburg, Oberdürrbacher Strasse 6, D - 97080 Würzburg, Germany. stoerk_s@klinik.uni-wuerzburg.de
Heart (British Cardiac Society)
|October 31, 2009
Summary
Low serum androgen levels in men with heart failure (HF) are linked to worse outcomes. However, this association is confounded by poor health status, suggesting androgens decrease as a consequence of HF progression.
Area of Science:
- Endocrinology
- Cardiology
- Clinical Medicine
Background:
- Anabolic sex steroid deficiency is common in heart failure (HF).
- The clinical significance of low serum androgen levels in HF remains incompletely understood.
- This study investigates the prognostic implications of androgen deficiency in male HF patients.
Purpose of the Study:
- To determine the association between serum androgen levels and prognosis in men with heart failure.
- To investigate the relationship between free testosterone, dehydroepiandrosterone sulfate (DHEAS), sex hormone-binding globulin (SHBG), and heart failure severity (NYHA class).
Main Methods:
- Prospective cohort study of 191 men with heart failure (mean age 64 years).
- Measurement of total and free serum testosterone, DHEAS, and SHBG.
- Follow-up for all-cause mortality over a median of 859 days.
Main Results:
- Reduced free testosterone (79%) and DHEAS (23%) were prevalent; total testosterone was mostly normal.
- Lower free testosterone and DHEAS, and higher SHBG were associated with increased mortality risk.
- These associations were attenuated after adjustment for confounding factors related to poor health status.
Conclusions:
- Low serum androgen levels in male HF patients correlate with adverse prognosis.
- The observed association is confounded by indicators of a poor health state.
- Low serum androgens likely result from the systemic effects of advanced heart failure.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...